Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Regulation Of The Level And Glycosylation State Of Plasminogen Activator Inhibitor Type 2 During Human Keratinocyte Differentiation.

Y. Wang, P. Jensen
Published 1998 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Plasminogen activator inhibitor type 2 (PAI-2) is an unusual member of the serine proteinase inhibitor (serpin) family which has been implicated in the protection of cells from programmed cell death. Human epidermal keratinocytes synthesize large amounts of PAI-2 in two active forms: glycosylated and non-glycosylated. Calcium (Ca2+), a well-known inducer of numerous aspects of keratinocyte terminal differentiation, increases the steady-state levels of PAI-2 mRNA and protein. As the cultures become more differentiated due to longer incubation with Ca2+, the glycosylated form is preferentially elevated. Surprisingly, glycosylated as well as non-glycosylated PAI-2 remains predominantly cell-associated, in a trypsin-inaccessible form and thus most likely inside the cell. Tumor necrosis factor-alpha (TNF-alpha), an inflammatory mediator that induces some markers of keratinocyte differentiation, also increases PAI-2 mRNA and protein levels. Experiments using cultures in which protein kinase C has been downregulated suggest that Ca2+, but not TNF-alpha, acts at least partially through one or more isozymes of this kinase for induction of PAI-2. This is consistent with the finding that the effect of simultaneous addition of Ca2+ plus TNF-alpha is at least additive, compared with addition of either stimulant alone. These data demonstrate that the keratinocyte maintains multiple regulatory pathways for control of PAI-2 expression, at least one of which is related to terminal differentiation.
This paper references
10.1002/j.1460-2075.1989.tb08489.x
Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2.
D. Belin (1989)
10.1002/JCP.1041450114
Modulation of growth and differentiation in normal human keratinocytes by transforming growth factor‐β
K. Matsumoto (1990)
10.1074/JBC.270.46.27894
Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.
J. Dickinson (1995)
10.1002/AJA.1001990303
Apoptosis in human skin development: Morphogenesis, periderm, and stem cells
R. Polakowska (1994)
10.1128/MCB.7.12.4564
Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells.
W. D. Schleuning (1987)
10.1111/j.1365-2249.1993.tb03457.x
Localization of tumour necrosis factor‐alpha (TNF‐α) and its receptors in normal and psoriatic skin: epidermal cells express the 55‐kD but not the 75‐kD TNF receptor
M. Kristensen (1993)
10.1002/JCP.1041100217
Clonal growth of normal human epidermal keratinocytes in a defined medium
M. Tsao (1982)
Apoptosis: the skin from a new perspective.
R. Polakowska (1994)
10.1016/0014-5793(93)81143-N
The ovalbumin family of serpin proteins
E. Remold-O'Donnell (1993)
10.1074/JBC.272.18.12035
S100A11, S100A10, Annexin I, Desmosomal Proteins, Small Proline-rich Proteins, Plasminogen Activator Inhibitor-2, and Involucrin Are Components of the Cornified Envelope of Cultured Human Epidermal Keratinocytes*
N. Robinson (1997)
10.1083/JCB.104.3.705
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells
C. Genton (1987)
10.1006/EXCR.1995.1064
Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope.
P. Jensen (1995)
10.1083/JCB.120.1.217
Coordinate changes in gene expression which mark the spinous to granular cell transition in epidermis are regulated by protein kinase C
A. Dlugosz (1993)
10.1084/JEM.172.6.1609
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light
A. Köck (1990)
10.1172/JCI113963
Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes.
S. Pillai (1989)
10.1084/JEM.165.2.320
Plasminogen activator-specific inhibitors produced by human monocytes/macrophages
A. Wohlwend (1987)
10.1111/1523-1747.EP12472297
Epidermal growth factor and insulin-like growth factor I enhance keratinocyte migration.
Y. Ando (1993)
10.1111/J.1432-1033.1993.TB17906.X
Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures.
P. Jensen (1993)
10.1074/jbc.270.40.23239
A Novel Matrix Attachment Region DNA Binding Motif Identified Using a Random Phage Peptide Library (*)
B. Wang (1995)
10.1002/(SICI)1097-4652(199606)167:3<500::AID-JCP14>3.0.CO;2-7
Protein kinase C mediates up‐regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro
Y. Ando (1996)
Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo.
P. Jensen (1996)
10.1111/1523-1747.EP12540422
Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture.
S. Boyce (1983)
10.1111/1523-1747.EP12478519
Programmed cell death in terminally differentiating keratinocytes: role of endogenous endonuclease.
C. McCall (1991)
10.1055/S-0038-1650624
Expression of plasminogen activator inhibitor 2 in the adult and embryonic mouse tissues.
Y. Kawata (1996)
10.1016/s0021-9258(18)67369-7
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.
E. K. Kruithof (1986)
10.1016/s0021-9258(18)54804-3
Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2.
S. Kumar (1991)
10.1111/J.1432-1033.1992.TB16769.X
Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells.
T. Antalis (1992)
10.1016/0014-4827(89)90316-9
Differentiation-linked expression of the plasminogen activator inhibitor type-2 gene in the human HL-60 promyelocytic cell line.
A. Arndt (1989)
Specific protein kinase C isozymes mediate the induction of keratinocyte differentiation markers by calcium.
M. Denning (1995)
10.1146/ANNUREV.BI.52.070183.003255
Human plasma proteinase inhibitors.
J. Travis (1983)
10.1139/O90-196
Induction of plasminogen activator inhibitor type 2 expression during differentiation of human K562 cells towards a macrophage phenotype.
A. Rehemtulla (1990)
Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium.
G. Shipley (1986)



This paper is referenced by
Brett Novel Consensus Motif Plasminogen Activator Inhibitor 2 via a Degradation by Interaction with the Serpin Inhibition of Retinoblastoma Protein
G. Darnell (2003)
10.1016/S0014-4827(02)00037-X
Regulation of trespin expression by modulators of cell growth, differentiation, and apoptosis in prostatic epithelial cells.
L. Stewart (2003)
10.1201/9780203912683.CH11
Immunobiologicals for Psoriasis: Using Targeted Immunotherapies as Pathogenic Probes in Psoriasis
G. Weinstein (2003)
10.1046/J.0022-202X.2001.01428.X
Sodium dodecyl sulfate induces plasminogen activator inhibitor type 2 expression in epidermal keratinocytes in vivo and in vitro.
N. M. Chung (2001)
Plasminogen activator inhibitor type 2 in human corneal epithelium.
D. Williams (1999)
10.1111/j.1440-0960.2006.00262.x
Immunopathogenesis of psoriasis
M. R. Lee (2006)
10.1111/J.1087-0024.2004.00831.X
Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances.
A. Gottlieb (2004)
10.1016/J.CLINDERMATOL.2003.08.015
Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.
Frank C Victor (2003)
10.1055/s-0031-1276589
Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.
Jodi A. Lee (2011)
10.4049/jimmunol.0902187
A Physiological Function of Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity
W. Schroder (2010)
10.1016/j.yexcr.2010.10.016
Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2.
L. Major (2011)
10.1007/s004180050318
Differentiating cells of murine stratified squamous epithelia constitutively express plasminogen activator inhibitor type 2 (PAI-2)
B. Risse (1998)
10.1289/ehp.11215
Transcriptome Analyses in Normal Prostate Epithelial Cells Exposed to Low-Dose Cadmium: Oncogenic and Immunomodulations Involving the Action of Tumor Necrosis Factor
Shlomo Bakshi (2008)
10.1002/(SICI)1097-4652(200002)182:2<281::AID-JCP17>3.0.CO;2-D
Evidence for intracellular cleavage of plasminogen activator inhibitor type 2 (PAI‐2) in normal epidermal keratinocytes
B. Risse (2000)
10.4103/0253-7613.42300
Novel immunobiologics for psoriasis
N. Ghosh (2008)
10.1093/glycob/cwv102
Sweating the small stuff: Glycoproteins in human sweat and their unexplored potential for microbial adhesion.
R. Peterson (2016)
10.1002/jcp.20398
Plasminogen activator inhibitor type 2 (PAI‐2) is present in normal human conjunctiva
M. Massaro-Giordano (2005)
10.1016/J.DET.2004.03.011
Psoriasis and its treatment with infliximab-mediated tumor necrosis factor α blockade
L. Winterfield (2004)
10.1016/S0190-9622(03)01143-5
Infliximab for psoriasis.
A. Gottlieb (2003)
Extracellular proteolysis and venous leg ulcer
M. Weckroth (2004)
Characterisation of SerpinB2 as a stress response modulator
Jodi A. Lee (2015)
10.1128/MCB.23.18.6520-6532.2003
Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif
G. Darnell (2003)
10.1016/J.CLINDERMATOL.2005.01.009
Psoriasis: a fresh look.
I. Galadari (2005)
10.1111/j.1396-0296.2004.04044.x
Infliximab
Laura S. Winterfield (2004)
10.1002/mc.22022
Dysregulated ΔNp63α negatively regulates the maspin promoter in keratinocytes via blocking endogenous p73 binding
K. King (2014)
10.1016/j.bone.2020.115673
Trps1 transcription factor represses phosphate-induced expression of SerpinB2 in osteogenic cells.
M. Socorro (2020)
Semantic Scholar Logo Some data provided by SemanticScholar